Deerfield Management Company, L.P. (Series C) Taysha Gene Therapies, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 5,386,000 shares of TSHA stock, worth $15.7 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
5,386,000Holding current value
$15.7 Million% of portfolio
0.29%Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
154Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$72.8 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$68.5 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$63.1 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$49.1 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$36.6 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $141M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...